Patrizia Sini

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <i>In vitro</i> and <i>In vivo</i> Antitumor Activity

Christine M. Chresta, Barry R. Davies, Ian Hickson et al. · Cancer Research · 2009 · 795 citations · Full text

Medicine, Oncology, Pharmacology +13

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

Heidi A. Lane, Jeanette M. Wood, Paul M.J. McSheehy et al. · Clinical Cancer Research · 2009 · 251 citations · Full text

Medicine, Oncology, Pharmacology +17

An effector region in Eps8 is responsible for the activation of the Rac-specific GEF activity of Sos-1 and for the proper localization of the Rac-based actin–polymerizing machine

Giorgio Scita, Pierluigi Tenca, Liliana B. Areces et al. · The Journal of Cell Biology · 2001 · 136 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +16

Abl-dependent tyrosine phosphorylation of Sos-1 mediates growth-factor-induced Rac activation

Patrizia Sini, Angela Cannas, Anthony J. Koleske et al. · Nature Cell Biology · 2004 · 134 citations

Life Sciences, Biochemistry, Molecular Biology +10

Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells

Patrizia Sini, Dominic I. James, Christine M. Chresta et al. · Autophagy · 2010 · 90 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17